Development of Collaboration Products Sample Clauses

The 'Development of Collaboration Products' clause defines the responsibilities and procedures for jointly creating products or deliverables between two or more parties. It typically outlines how the parties will contribute resources, share information, and coordinate efforts during the development process, and may specify ownership rights, milestones, or approval processes for the resulting products. This clause ensures that all parties have a clear understanding of their roles and expectations, reducing the risk of disputes and facilitating efficient, cooperative product development.
Development of Collaboration Products. BMS shall have the sole right to select and approve a Collaboration Compound for further characterization and pre-clinical development as a lead compound, which occurs when formal assignment of chemistry resources for a fully integrated discovery program have been assigned to such Collaboration Compound as reflected in the minutes of the meetings of the BMS Drug Development Management Committee, after reasonably considering any recommendations of the JRC. Once a Collaboration Compound is selected for preclinical development, BMS shall be solely responsible for and shall have the sole right to develop the Collaboration Compound through preclinical development, all phases of clinical trials, and making all applications for and obtaining all Regulatory Approvals on a worldwide basis. [*].
View Source
Development of Collaboration Products. 4.1 Development of Protein Candidate Products and Genentech Advanced Research Products. (a) Exclusive Right to Develop and Commercialize. Genentech shall have the sole right and responsibility for, and control over, developing and commercializing Protein Candidate Products and Genentech Advanced Research Products; provided, however, that with regard to Restricted Rights Projects, nothing in this Section 4.1(a) will be deemed to grant Genentech rights beyond the scope of the licenses granted to Genentech (or limit the rights of Lexicon, its collaborators or licensees) with regard to such Restricted Rights Project. (b) Transfer to Genentech of Lexicon Pre-Existing Know-How, Restricted Rights Project Know-How and Project Know-How. Within [**] days after designation of a Protein Candidate pursuant to Section 3.5 or a Genentech Advanced Research Protein Candidate pursuant to Section 3.7, Lexicon will provide Genentech, to the extent not previously provided, with a copy of all Lexicon Pre-Existing Know-How, Project Know-How and Restricted Rights Project Know-How in Lexicon's possession or control related to such Protein Candidate or Genentech Advanced Research Protein Candidate.
View Source
Development of Collaboration Products 
View SourceView Similar (9)

Related to Development of Collaboration Products

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.